Eain Anthony Murphy

Dr. Eain Anthony Murphy


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KRKathryn L. Roche
Kathryn L. Roche
SRStacy Remiszewski
Stacy Remiszewski
MTMatthew J. Todd
Matthew J. Todd
JKJohn L Kulp
John L Kulp
LTLiudi Tang
Liudi Tang
LCLillian W. Chiang
Lillian W. Chiang
Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD+-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at multiple levels to antagonize cytomegalovirus replication in fibroblasts, causing modest reductions in viral RNAs and DNA, together with a much greater reduction in infectious progeny, and it exhibits antiviral activity in humanized mouse models of infection. Our results highlight the potential of sirtuin 2 inhibitors as broad-spectrum antivirals and set the stage for further understanding of how host epigenetic mechanisms impact the growth and spread of viral pathogens.

15 April 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
COChristine M. O'COnnor
Christine M. O'COnnor
MNMasatoshi Nukui
Masatoshi Nukui
KGKaterina V. Gurova
Katerina V. Gurova
EMEain Anthony Murphy
Eain Anthony Murphy
The successful colonization of the majority of the population by human cytomegalovirus is a direct result of the virus's ability to establish and, more specifically, reactivate from latency. The underlying cellular factors involved in viral reactivation remain unknown. Here, we show that the host complex fa cilitates c hromatin t ranscription (FACT) binds to the major immediate early promoter (MIEP) and that inhibition of this complex reduces MIEP transactivation, thus inhibiting viral reactivation.

17 August 2020 in Journal of Virology
Verified
Journal Article
Closed access
MNMasatoshi Nukui
Masatoshi Nukui
KRKathryn L. Roche
Kathryn L. Roche
JJJie Jia
Jie Jia
PFPaul L. Fox
Paul L. Fox
EMEain Anthony Murphy
Eain Anthony Murphy
In order for a pathogen to establish a successful infection, it must undermine the host cell responses inhibitory to the pathogen. As such, herpesviruses encode multiple viral proteins that antagonize each host antiviral response, thereby allowing for efficient viral replication. Human Cytomegalovirus encodes several factors that limit host countermeasures to infection, including pp71. Herein, we identified a previously unreported posttranslational modification of pp71, protein S-nitrosylation. Using site-directed mutagenesis, we mutated the specific sites of this modification thereby blocking this pp71 posttranslational modification. In contexts where pp71 is not protein S-nitrosylated, host antiviral response was inhibited. The net result of this posttranslational modification is to render a viral protein with diminished abilities to block host responses to infection. This novel work supports a model in which protein S-nitrosylation may be an additional mechanism in which a cell inhibits a pathogen during the course of infection.

28 February 2023 in Journal of Virology
Verified
Journal Article
Open access
FGFelicia Goodrum
Felicia Goodrum
ALAnice C. Lowen
Anice C. Lowen
Seema  LakdawalaSeema Lakdawala
Seema Lakdawala
JAJames Alwine
James Alwine
ACArturo Casadevall
Arturo Casadevall
AYAndrew Yurochko
Andrew Yurochko
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals.

26 March 2025 in Brain Pathology
Verified
Journal Article
Open access
EIEmmanuel C. Ijezie
Emmanuel C. Ijezie
MMMichael J. Miller
Michael J. Miller
CHCeline Hardy
Celine Hardy
AJAva R. Jarvis
Ava R. Jarvis
TCTimothy F. Czajka
Timothy F. Czajka
DBDavid C. Butler
David C. Butler
Herpes simplex virus 1 (HSV‐1) infection alters critical markers of Alzheimer's disease (AD) in neurons. One key marker of AD is the hyperphosphorylation of Tau, accompanied by altered levels of Tau isoforms. However, an imbalance in these Tau splice variants, specifically resulting from altered 3R to 4R MAPT splicing of exon 10, has yet to be directly associated with HSV‐1 infection. To this end, we infected 2D and 3D human neural models with HSV‐1 and monitored MAPT splicing and Tau phosphorylation. Further, we transduced SH‐SY5Y neurons with HSV‐1 ICP27, which alters RNA splicing, to analyze if ICP27 alone is sufficient to induce altered MAPT exon 10 splicing. We show that HSV‐1 infection induces altered splicing of MAPT exon 10, increasing 4R‐Tau protein levels, Tau hyperphosphorylation, and Tau oligomerization. Our experiments reveal a novel link between HSV‐1 infection and the development of cytopathic phenotypes linked with AD progression.

1 November 2018 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
KRKathryn L. Roche
Kathryn L. Roche
MNMasatoshi Nukui
Masatoshi Nukui
BKBenjamin A. Krishna
Benjamin A. Krishna
COChristine O'Connor
Christine O'Connor
EMEain Anthony Murphy
Eain Anthony Murphy
HCMV is a significant pathogen that accounts for a substantial amount of complications within the immunosuppressed and immunocompromised. Of particular significance is the capacity of HCMV to reactivate within solid tissue and bone marrow transplant recipients. While it is known that HCMV latency resides within a fraction of HPCs and monocytes, the exact subset of cells that harbor latent viral genomes during natural infections remain uncharacterized. The capacity to identify changes within the host transcriptome during latent infections is critical for developing approaches that therapeutically or physically eliminate latent viral genome containing cells and will represent a major breakthrough for reducing complications due to HCMV reactivation posttransplant. In this report, we describe the generation and use of a recombinant HCMV that allows specific and distinct labeling of RNA species that are produced within virally infected cells. This is a critical first step in identifying how HCMV affects the host cell during latency and more importantly, allows one to characterize cells that harbor latent HCMV.